Global Markets Direct’s, ‘Colon Cancer – Pipeline Review, H1 2015′, provides an overview of the Colon Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Colon Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colon Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Colon Cancer
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Colon Cancer and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Colon Cancer pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Colon Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
Introduction 7
Colon Cancer Overview 8
Therapeutics Development 9
Colon Cancer - Therapeutics under Development by Companies 11
Colon Cancer - Therapeutics under Investigation by Universities/Institutes 21
Colon Cancer - Pipeline Products Glance 26
Colon Cancer - Products under Development by Companies 29
Colon Cancer - Products under Investigation by Universities/Institutes 39
Colon Cancer - Companies Involved in Therapeutics Development 43
Colon Cancer - Therapeutics Assessment 135
Drug Profiles 152
Colon Cancer - Recent Pipeline Updates 422
Colon Cancer - Dormant Projects 487
Colon Cancer - Discontinued Products 500
Colon Cancer - Product Development Milestones 501
Appendix 508

List of Tables

Number of Products under Development for Colon Cancer, H1 2015 31
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 34
Number of Products under Development by Companies, H1 2015 (Contd..1) 35
Number of Products under Development by Companies, H1 2015 (Contd..2) 36
Number of Products under Development by Companies, H1 2015 (Contd..3) 37
Number of Products under Development by Companies, H1 2015 (Contd..4) 38
Number of Products under Development by Companies, H1 2015 (Contd..5) 39
Number of Products under Development by Companies, H1 2015 (Contd..6) 40
Number of Products under Development by Companies, H1 2015 (Contd..7) 41
Number of Products under Development by Companies, H1 2015 (Contd..8) 42
Number of Products under Investigation by Universities/Institutes, H1 2015 44
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 45
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 46
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 47
Comparative Analysis by Late Stage Development, H1 2015 48
Comparative Analysis by Clinical Stage Development, H1 2015 49
Comparative Analysis by Early Stage Development, H1 2015 50
Products under Development by Companies, H1 2015 51
Products under Development by Companies, H1 2015 (Contd..1) 52
Products under Development by Companies, H1 2015 (Contd..2) 53
Products under Development by Companies, H1 2015 (Contd..3) 54
Products under Development by Companies, H1 2015 (Contd..4) 55
Products under Development by Companies, H1 2015 (Contd..5) 56
Products under Development by Companies, H1 2015 (Contd..6) 57
Products under Development by Companies, H1 2015 (Contd..7) 58
Products under Development by Companies, H1 2015 (Contd..8) 59
Products under Development by Companies, H1 2015 (Contd..9) 60
Products under Investigation by Universities/Institutes, H1 2015 61
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 62
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 63
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 64
Colon Cancer - Pipeline by Aduro BioTech, Inc., H1 2015 65
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 66
Colon Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 67
Colon Cancer - Pipeline by AGV Discovery, SAS, H1 2015 68
Colon Cancer - Pipeline by AIMM Therapeutics B.V., H1 2015 69
Colon Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 70
Colon Cancer - Pipeline by AlphaVax, Inc., H1 2015 71
Colon Cancer - Pipeline by Ambrx, Inc., H1 2015 72
Colon Cancer - Pipeline by Anavex Life Sciences Corp., H1 2015 73
Colon Cancer - Pipeline by AndroScience Corporation, H1 2015 74
Colon Cancer - Pipeline by ANP Technologies, Inc., H1 2015 75
Colon Cancer - Pipeline by Aphios Corporation, H1 2015 76
Colon Cancer - Pipeline by Apogenix GmbH, H1 2015 77
Colon Cancer - Pipeline by Aposense Ltd., H1 2015 78
Colon Cancer - Pipeline by AstraZeneca Plc, H1 2015 79
Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2015 80
Colon Cancer - Pipeline by Bavarian Nordic A/S, H1 2015 81
Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2015 82
Colon Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2015 83
Colon Cancer - Pipeline by Bionomics Limited, H1 2015 84
Colon Cancer - Pipeline by Carna Biosciences, Inc., H1 2015 85
Colon Cancer - Pipeline by Celyad, H1 2015 86
Colon Cancer - Pipeline by Cold Genesys, Inc., H1 2015 87
Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2015 88
Colon Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 89
Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2015 90
Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2015 91
Colon Cancer - Pipeline by CZ BioMed Corp, H1 2015 92
Colon Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 93
Colon Cancer - Pipeline by DEKK-TEC, Inc., H1 2015 94
Colon Cancer - Pipeline by Digna Biotech, S.L., H1 2015 95
Colon Cancer - Pipeline by EntreChem, S.L., H1 2015 96
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 97
Colon Cancer - Pipeline by GlycaNova Norway AS, H1 2015 98
Colon Cancer - Pipeline by Histogen, Inc., H1 2015 99
Colon Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2015 100
Colon Cancer - Pipeline by Ignyta, Inc., H1 2015 101
Colon Cancer - Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 102
Colon Cancer - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2015 103
Colon Cancer - Pipeline by Immunomedics, Inc., H1 2015 104
Colon Cancer - Pipeline by Immunotope, Inc., H1 2015 105
Colon Cancer - Pipeline by Innopharmax Inc., H1 2015 106
Colon Cancer - Pipeline by Intezyne, Inc, H1 2015 107
Colon Cancer - Pipeline by Intrexon Corporation, H1 2015 108
Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 109
Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2015 110
Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2015 111
Colon Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 112
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 113
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2015 114
Colon Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 115
Colon Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 116
Colon Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2015 117
Colon Cancer - Pipeline by MolMed S.p.A., H1 2015 118
Colon Cancer - Pipeline by Multimmune GmbH, H1 2015 119
Colon Cancer - Pipeline by Nanobiotix, H1 2015 120
Colon Cancer - Pipeline by Nektar Therapeutics, H1 2015 121
Colon Cancer - Pipeline by Novartis AG, H1 2015 122
Colon Cancer - Pipeline by Omeros Corporation, H1 2015 123
Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015 124
Colon Cancer - Pipeline by Oncology Research International Limited, H1 2015 125
Colon Cancer - Pipeline by OncoVista Innovative Therapies, Inc., H1 2015 126
Colon Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 127
Colon Cancer - Pipeline by Orega Biotech SAS, H1 2015 128
Colon Cancer - Pipeline by OSE Pharma SA, H1 2015 129
Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2015 130
Colon Cancer - Pipeline by Panacela Labs, Inc., H1 2015 131
Colon Cancer - Pipeline by PharmAbcine, Inc., H1 2015 132
Colon Cancer - Pipeline by Pharminox Limited, H1 2015 133
Colon Cancer - Pipeline by Philogen S.p.A., H1 2015 134
Colon Cancer - Pipeline by Pique Therapeutics, H1 2015 135
Colon Cancer - Pipeline by Plexxikon Inc., H1 2015 136
Colon Cancer - Pipeline by Priaxon AG, H1 2015 137
Colon Cancer - Pipeline by Provecs Medical GmbH, H1 2015 138
Colon Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2015 139
Colon Cancer - Pipeline by Qu Biologics Inc., H1 2015 140
Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 141
Colon Cancer - Pipeline by Sareum Holdings Plc, H1 2015 142
Colon Cancer - Pipeline by Sigma-Tau S.p.A., H1 2015 143
Colon Cancer - Pipeline by Sirnaomics, Inc., H1 2015 144
Colon Cancer - Pipeline by Starpharma Holdings Limited, H1 2015 145
Colon Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 146
Colon Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 147
Colon Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2015 148
Colon Cancer - Pipeline by Transgene Biotek Limited, H1 2015 149
Colon Cancer - Pipeline by TVAX Biomedical, Inc., H1 2015 150
Colon Cancer - Pipeline by Tyg Oncology Ltd., H1 2015 151
Colon Cancer - Pipeline by Vaccinogen, Inc., H1 2015 152
Colon Cancer - Pipeline by Viventia Biotechnologies Inc., H1 2015 153
Colon Cancer - Pipeline by vTv Therapeutics Inc., H1 2015 154
Colon Cancer - Pipeline by Yakult Honsha Co., Ltd., H1 2015 155
Colon Cancer - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2015 156
Assessment by Monotherapy Products, H1 2015 157
Assessment by Combination Products, H1 2015 158
Number of Products by Stage and Target, H1 2015 160
Number of Products by Stage and Mechanism of Action, H1 2015 166
Number of Products by Stage and Route of Administration, H1 2015 171
Number of Products by Stage and Molecule Type, H1 2015 173
Colon Cancer Therapeutics - Recent Pipeline Updates, H1 2015 444
Colon Cancer - Dormant Projects, H1 2015 509
Colon Cancer - Dormant Projects (Contd..1), H1 2015 510
Colon Cancer - Dormant Projects (Contd..2), H1 2015 511
Colon Cancer - Dormant Projects (Contd..3), H1 2015 512
Colon Cancer - Dormant Projects (Contd..4), H1 2015 513
Colon Cancer - Dormant Projects (Contd..5), H1 2015 514
Colon Cancer - Dormant Projects (Contd..6), H1 2015 515
Colon Cancer - Dormant Projects (Contd..7), H1 2015 516
Colon Cancer - Dormant Projects (Contd..8), H1 2015 517
Colon Cancer - Dormant Projects (Contd..9), H1 2015 518
Colon Cancer - Dormant Projects (Contd..10), H1 2015 519
Colon Cancer - Dormant Projects (Contd..11), H1 2015 520
Colon Cancer - Dormant Projects (Contd..12), H1 2015 521
Colon Cancer - Discontinued Products, H1 2015 522

List of Figures

Number of Products under Development for Colon Cancer, H1 2015 31
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2015 32
Number of Products under Development by Companies, H1 2015 33
Number of Products under Investigation by Universities/Institutes, H1 2015 43
Comparative Analysis by Clinical Stage Development, H1 2015 49
Comparative Analysis by Early Stage Products, H1 2015 50
Assessment by Monotherapy Products, H1 2015 157
Number of Products by Top 10 Targets, H1 2015 159
Number of Products by Stage and Top 10 Targets, H1 2015 159
Number of Products by Top 10 Mechanism of Actions, H1 2015 165
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 165
Number of Products by Top 10 Routes of Administration, H1 2015 170
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 170
Number of Products by Top 10 Molecule Types, H1 2015 172
Number of Products by Stage and Top 10 Molecule Types, H1 2015 172